VICL | tickerfilter.com

Fundamental analysis

47%

Profitability 60%

Dept financing 2%

Liquidity 36%

Performance 49%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

0 0%

Key data

Stock price

$0.68

P/E Ratio

N/A

DAY RANGE

$0.68 - $0.68

EPS

-$0.55

52 WEEK RANGE

$0.60 - $1.47

52 WEEK CHANGE

-$53.70

MARKET CAP

15.532 M

YIELD

N/A

SHARES OUTSTANDING

22.841 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

$20,138,910

AVERAGE 10 VOLUME

$1,893,840

AVERAGE 30 VOLUME

$1,120,236

Company detail

CEO: Vijay B. Samant
Region: US
Website: http://www.vical.com
Employees: 30
IPO year: -

Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.

VICL - Vical Incorporated